UCB

Contact
ucb-group.com
+3225599999

UCB Pharma S.A.

Allée de la Recherche, 60
1070 Brüssel
Belgium
+3225599999
ucb-group.com
Contact
Profile Products News
Contact

About UCB

With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in three therapeutic areas - CNS, inflammation and oncology.

Read more about UCB
Facts about UCB
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of UCB

Product portfolio

Show all

News about UCB

UCB

21-Oct-2016 | business & finance

Evotec and UCB sign multi-year CNS pharmacology agreement

Evotec AG announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Under the terms of the three-year agreement, ...

Read news
UCB

25-Feb-2016 | science

Major pharma companies sign up to groundbreaking Parkinson's consortium

Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and ...

Read news
UCB

11-Feb-2016 | science

UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration

Strategic collaboration to discover transformational therapies for neurodegenerative disease

Read news
UCB

30-Jul-2015 | research and development

UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

UCB announced that the two EMBODY™ Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet their primary clinical ...

Read news
UCB

07-Apr-2015 | business & finance

UCB to focus on core business in India

UCB to sell its established brands portfolio in India to Dr. Reddy’s for € 118 million

Read news
UCB

31-Mar-2015 | business & finance

UCB secures multimillion pound funding boost from UK Government

UCB announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing ...

Read news
UCB

13-Jan-2015 | research and development

Dermira and UCB announce start of Phase 3 program for CIMZIA® (certolizumab pegol) in psoriasis

Dermira, Inc. and UCB announced that the first patients have been dosed in the Phase 3 clinical program designed to evaluate the efficacy and safety of ...

Read news
UCB

10-Nov-2014 | business & finance

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million

UCB, Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, announced they have entered into a ...

Read news
Show more news about UCB

Here you will find UCB Pharma S.A.